Related references
Note: Only part of the references are listed.Second surgery for recurrent glioblastoma: advantages and pitfalls
Alba A. Brandes et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
The Role of MGMT Testing in Clinical Practice A Report of the Association for Molecular Pathology
Milena Cankovic et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia et al.
EUROPEAN JOURNAL OF CANCER (2012)
An extent of resection threshold for newly diagnosed glioblastomas
Nader Sanai et al.
JOURNAL OF NEUROSURGERY (2011)
Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States
Stuart A. Grossman et al.
CLINICAL CANCER RESEARCH (2010)
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
John K. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
J. Sadones et al.
EUROPEAN JOURNAL OF CANCER (2009)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
M Lacroix et al.
JOURNAL OF NEUROSURGERY (2001)
Share Paper
